Circulating Sclerostin Levels Are Positively Related to Coronary Artery Disease Severity and Related Risk Factors

Romosozumab is a newly available treatment for osteoporosis acting by sclerostin inhibition. Its cardiovascular safety has been questioned after finding excess cardiovascular disease (CVD)‐related events in a pivotal phase 3 trial. Previous studies of relationships between circulating sclerostin lev...

Descripción completa

Detalles Bibliográficos
Autores principales: Frysz, Monika, Gergei, Ingrid, Scharnagl, Hubert, Smith, George Davey, Zheng, Jie, Lawlor, Deborah A, Herrmann, Markus, Maerz, Winfried, Tobias, Jon H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377011/
https://www.ncbi.nlm.nih.gov/pubmed/34738659
http://dx.doi.org/10.1002/jbmr.4467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377011/
https://www.ncbi.nlm.nih.gov/pubmed/34738659
http://dx.doi.org/10.1002/jbmr.4467

Ejemplares similares